ASLAN004 shows proof of concept in atopic dermatitis treatment
Click Here to Manage Email Alerts
WAILEA, Hawaii — A proof-of-concept study of ASLAN004 found it to be safe and efficacious in treating moderate to severe atopic dermatitis, according to a poster presented at Maui Derm for Dermatologists.
“ASLAN004 is a fully human [monoclonal antibody] with a novel mechanism of action that binds with high affinity to [interleukin (IL)]-13R1 and specifically inhibits both IL-4 and IL-13 signaling via the Type 2 cytokine receptor, an important biologic target in atopic dermatitis,” Karen A. Veverka, vice president and head of medical at ASLAN Pharmaceuticals in Menlo Park, California, and colleagues wrote.
This study included 25 adult AD patients from the United States, Australia and Singapore who were randomly assigned 3:1 to receive 200 mg, 400 mg or 600 mg of subcutaneous ASLAN004 or placebo weekly.
Three patients discontinued treatment due to COVID-19 restrictions, and 18 of the patients completed at least 29 days of dosing and assessment.
At week 8, a mean reduction in Eczema Area and Severity Index score for the 200 mg group was 50%, while the 400 mg and 600 mg groups had mean reductions of 74% and 76%, respectfully. The placebo group had a mean reduction in EASI of 42%.
Mean peak pruritus reductions were 34%, 48% and 39% for the three treatment groups, compared with 16% for the placebo group.
No drug-related treatment emergent adverse events led to discontinuation.
“ASLAN004 was well tolerated, with 400 mg and 600 mg showing promising efficacy in adults with moderate to severe AD,” the authors wrote.
Collapse
Veverka KA, et al. Poster. Interim analysis results from a proof-of-concept study for ASLAN004 in adult moderate to severe atopic dermatitis: A randomized, placebo-controlled study. Presented at: Maui Derm for Dermatologists; Jan. 24-28, 2022; Wailea, Hawaii.
Read more about
Click Here to Manage Email Alerts